CHICAGO: Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence-driven precision medicine, announced Friday it has acquired Paige, a digital pathology company known for pioneering FDA-cleared AI applications in cancer detection.
The $81.25 million deal, primarily paid in Tempus common stock, positions Tempus to expand its oncology-focused dataset and technical capabilities.
Founded in 2017, Paige has built one of the world’s largest digital pathology datasets, comprising nearly 7 million de-identified slide images and associated clinical data. Its technology spans 45 countries and diverse populations, enabling the development of the first million-slide foundation model for cancer. Paige’s tools help researchers and clinicians make more informed treatment decisions by improving cancer detection and understanding.
“As we embark upon building the largest foundation model in oncology, acquiring Paige substantially accelerates our efforts,” said Tempus CEO Eric Lefkofsky. “Their team and dataset will be catalytic across all our AI initiatives.”
Paige CEO Razik Yousfi added, “By joining forces with Tempus, we can bring our innovations to a broader patient population and deliver even greater impact.”
The acquisition also includes Tempus assuming Paige’s remaining commitment under its Microsoft Azure cloud services agreement.